Originally published by our sister publication, Infectious Disease Special Edition
Data from an independent study in Italy over 18 influenza seasons demonstrated that an adjuvanted trivalent vaccine (aTIV; Fluad Seqirus) was associated with a 12% lower risk for hospitalization and a 37% lower risk for respiratory-related hospitalizations compared with standard-dose, non-adjuvanted trivalent influenza vaccine (TIV) and standard-dose quadrivalent influenza vaccine (QIV).
In addition, two studies